Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis

Not Applicable

Terminated

• Conditions: Pelvic Pain
• Interventions: Other: Placebo; Other: Electro-kinetically Modified Water

• Registration Number: NCT02523794
• Lead Sponsor: Revalesio Corporation

Brief Summary

The purpose of this study is to evaluate the efficacy of electro-kinetically modified water (EMW) beverage, consumed twice daily (BID) for 3 months in the management of endometriosis associated pain, and to evaluate the effect of EMW consumption on analgesic use for endometriosis associated pain.

Detailed Description

This is a single center, double-blind, placebo controlled, randomized study to assess the efficacy of EMW versus placebo in the treatment of premenopausal women (16-49 years of age) with endometriosis associated pain. Approximately 40 subjects with endometriosis will be enrolled at Madigan Army Medical Center (MAMC). Subjects will be asked to consume EMW (or placebo) for three months. Subjects will record daily pain levels and other symptoms associated with endometriosis in an electronic diary. In addition to standard of care for this condition, the investigator will monitor the subjects at baseline, Month 1, and Month 3 visits, which will consist of patient questionnaires, blood sampling, and Adverse Events monitoring.

Study Timeline

• Study Start: 2015-08
• Study First Submitted: 2015-08-06
• Study First Submitted QC: 2015-08-12
• Study First Posted: 2015-08-14
• Primary Completion: 2016-09
• Study Completion: 2016-09
• Status Verified: 2018-01
• Last Update Submitted: 2018-01-23
• Last Update Posted: 2018-01-25

Recruitment & Eligibility

• Status: TERMINATED
• Sex: Female
• Target Recruitment: 9

Inclusion Criteria

• Premenopausal women, 16 to 49 years of age
• Diagnosed with endometriosis by means of documented surgical visualization (laparoscopy or laparotomy) within 10 years of study entry
• No endometriosis-related surgical procedures within a month of starting study agent
• Has at least 2 days of moderate or severe pain scores for dysmenorrhea (E-diary NRS > 5 of 10) and non-menstrual pelvic pain (E-diary NRS > 5 of 10) during the month prior to starting study agent
• Must have had a menstrual cycle of interval 24-35 days within 3 months of starting study agent
• BMI 18 to 39
• Able to provide written informed consent and able to comply with study procedures for the entire length of the study

Exclusion Criteria

• Pregnant or breastfeeding or planning pregnancy in the next 12 months
• Has been pregnant within 3 months of starting study agent
• Has had a hysterectomy or bilateral oophorectomy
• Has chronic pelvic pain not caused by endometriosis (i.e. inflammatory bowl disease, irritable bowel syndrome, adenomyosis, interstitial cystitis, pelvic adhesive disease, pelvic inflammatory disease) that requires chronic analgesic or narcotic use which would interfere with assessment of endometriosis associated pain
• Current history of undiagnosed abnormal uterine bleeding
• Currently receiving Gonadotropin-releasing hormone (GnRH) agonist or GnRH antagonist or have received any of these types of medications within 6 months of starting study agent
• Currently receiving subcutaneous medroxyprogesterone acetate (DMPA-SC) or i.m. medroxyprogesterone acetate (DMPA-IM) or have received any of these within the last 3 months of enrollment
• Currently has an intrauterine device in place
• Use of steroids or immunosuppressive medications on a regular basis within 3 months of enrollment
• Has an unstable medical condition, chronic disease or psychiatric disorder that is deemed by the investigator to be incompatible with participation in the study
• Treatment with any other investigational drug/interventions within 3 months of starting study agent
• History of drug or alcohol abuse

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Subjects will drink 2 to 3 500 mL bottles of purified drinking water daily for 3 months
Electro-kinetically Modified Water	Electro-kinetically Modified Water	Subjects will drink 2 to 3 500 mL bottles of EMW daily for 3 months

Primary Outcome Measures

Name	Time	Method
Change in endometriosis symptoms using the Composite Pelvic Signs and Symptoms Scale (CPSSS) total composite score.	3 Months

Secondary Outcome Measures

Name	Time	Method
Change in dysmenorrhea score on the CPSSS.	3 months
Change in use of rescue analgesia	3 months
Change in non-menstrual pelvic pain score on the CPSSS.	3 month
Change in endometrioma size as measured by TVUS	3 months
Change in premenstrual spotting from baseline on a numerical rating scale (NRS)	3 month
Change in endometriosis symptoms using the Endometriosis Health Profile (EHP-30) questionnaire.	3 months
Change in dyspareunia score on the CPSSS.	3 months

Trial Locations

Locations (1)

Madigan Army Medical Center; 🇺🇸 Tacoma, Washington, United States